Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 43 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H2 2015', provides an overview of the Burkholderia pseudomallei Infections (Melioidosis)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Burkholderia pseudomallei Infections (Melioidosis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burkholderia pseudomallei Infections (Melioidosis) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Burkholderia pseudomallei Infections (Melioidosis)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Burkholderia pseudomallei Infections (Melioidosis) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Burkholderia pseudomallei Infections (Melioidosis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Burkholderia pseudomallei Infections (Melioidosis) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Burkholderia pseudomallei Infections (Melioidosis)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Burkholderia pseudomallei Infections (Melioidosis) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Burkholderia pseudomallei Infections (Melioidosis) Overview 6
Therapeutics Development 7
Pipeline Products for Burkholderia pseudomallei Infections (Melioidosis) - Overview 7
Pipeline Products for Burkholderia pseudomallei Infections (Melioidosis) - Comparative Analysis 8
Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics under Development by Companies 9
Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics under Investigation by Universities/Institutes 10
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Products Glance 11
Early Stage Products 11
Burkholderia pseudomallei Infections (Melioidosis) - Products under Development by Companies 12
Burkholderia pseudomallei Infections (Melioidosis) - Products under Investigation by Universities/Institutes 13
Burkholderia pseudomallei Infections (Melioidosis) - Companies Involved in Therapeutics Development 14
Bavarian Nordic A/S 14
Emergent BioSolutions Inc. 15
Soligenix, Inc. 16
Syntiron LLC 17
Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
Burkholderia pseudomallei vaccine - Drug Profile 26
Mechanism of Action 26
R&D Progress 26
Burkholderia vaccine - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
dusquetide - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
GC-072 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
SGX-101 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
SGX-943 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecules to Inhibit InhA for Infectious Diseases - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Burkholderia pseudomallei Infections (Melioidosis) - Recent Pipeline Updates 35
Burkholderia pseudomallei Infections (Melioidosis) - Dormant Projects 37
Burkholderia pseudomallei Infections (Melioidosis) - Discontinued Products 38
Burkholderia pseudomallei Infections (Melioidosis) - Product Development Milestones 39
Featured News & Press Releases 39
Feb 11, 2015: Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC 39
Aug 14, 2014: US DTRA to fund preclinical work on Evolva's antibiotic GC-072 39
Feb 21, 2014: Bavarian Nordic's MVA-BN Vaccine Platform Selected by U.S. Department of Defense for New Vaccine Development 39
Feb 14, 2014: Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis 40
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 42
Disclaimer 43

List of Tables

Number of Products under Development for Burkholderia pseudomallei Infections (Melioidosis), H2 2015 7
Number of Products under Development for Burkholderia pseudomallei Infections (Melioidosis) - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Early Stage Development, H2 2015 11
Products under Development by Companies, H2 2015 12
Products under Investigation by Universities/Institutes, H2 2015 13
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Bavarian Nordic A/S, H2 2015 14
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Emergent BioSolutions Inc., H2 2015 15
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Soligenix, Inc., H2 2015 16
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Syntiron LLC, H2 2015 17
Assessment by Monotherapy Products, H2 2015 18
Number of Products by Stage and Target, H2 2015 19
Number of Products by Stage and Mechanism of Action, H2 2015 21
Number of Products by Stage and Route of Administration, H2 2015 23
Number of Products by Stage and Molecule Type, H2 2015 25
Burkholderia pseudomallei Infections (Melioidosis) Therapeutics - Recent Pipeline Updates, H2 2015 35
Burkholderia pseudomallei Infections (Melioidosis) - Dormant Projects, H2 2015 37
Burkholderia pseudomallei Infections (Melioidosis) - Discontinued Products, H2 2015 38